Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 trial of its lead drug for idiopathic pulmonary fibrosis (IPF) after seeing a ...

Commenting on the Champions Initiative, Cradle co-founder and chief executive Stef van Grieken said that technological ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

To avoid a tug-of-war between scientific rigour and operational efficiency, we must focus on the user and data journeys of ...

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

In a notice, the NIH said that indirect costs accounted for around $9 billion of its $35 billion funding spend in fiscal 2023 ...

As we close out the year, pharmaphorum's editorial team sat down together for a roundtable discussion of some of the biggest trends they tracked this year in the world of pharma. Join editor-in ...

An experimental therapy for Parkinson's disease being developed by Roche and Prothena has missed the mark in a phase 2b trial, leaving them sifting through the data for signals of efficacy.

China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates to the global pipeline. Despite more treatment options being a positive, Ben ...

As prescription drug abuse has grown in the US and Europe, the diversion of such treatments from legitimate sources has also increased. Ben Hargreaves speaks to an expert in the area to learn how ...

Celadon Pharmaceuticals has secured the final approval needed to start a large-scale trial of its cannabinoid therapy for chronic pain in the UK. The AIM-listed company said this morning that the ...

Rumours that Donald Trump had chosen Martin Makary as FDA Commissioner have been confirmed, while the President-Elect has also selected Dave Weldon to lead the Centers for Disease Control and ...